U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07779018) titled 'CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy' on Aug. 19.
Brief Summary: The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Intervention:
DRUG: CD22/CD19 CAR-T cell immunotherapy
Patients who achieved complete response (CR) after standard second-line chemotherapy will receive CD19/CD22 CAR-T cell immunotherapy as consolidation treatment. Auto...